Volatile organic compounds as a diagnostic tool for malignant pleural mesothelioma by Lamote, Kevin et al.
Volatile Organic Compounds as a Diagnostic Tool for Malignant Pleural Mesothelioma. 
Kevin Lamote1; Joris Van Cleemput2; Kristiaan Nackaerts3; Jan P. van Meerbeeck4 
1Dpt of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium, 2Occupational Health Service, Eternit NV, Kapelle-op-Den-Bos, Belgium,  
3Dpt of Respiratory Medicine, University Hospital Gasthuisberg, Leuven, Belgium, 4Thoracic Oncology/MOCA, Antwerp University Hospital, Antwerp, Belgium. 
Background 
Methods 
Results 
Conclusions 
• Malignant pleural mesothelioma (MPM) is a disease with a long latency period 
and a dismal prognosis. Early diagnosis of MPM can improve patients’ outcome 
but is hampered by non-specific symptoms and investigations, which delay 
diagnosis and result in advanced stage disease [van Meerbeeck JP, 2011]. An 
accurate non-invasive test allowing early stage diagnosis in asbestos-exposed 
persons is currently lacking and blood biomarkers have not proven to be useful. 
 
• Breathomics aims at a non-invasive analysis of volatile organic compounds 
(VOCs) in breath reflecting the cells’ metabolism. Recently, it was possible to 
discriminate MPM from controls using an electronic nose [Chapman EA 2009, 
Dragonieri S 2011]. However, the breathogram of MPM obtained by this eNose 
does not allow identification of MPM-related VOCs. Ion mobility spectrometry 
(IMS) combines the advantages of online direct sampling with the possibility of 
VOC identification and linking to MPM pathogenesis [Baumbach JI 2009].  
 
• With a non-targeted approach, we investigated which VOCs could play a role in 
MPM pathogenesis in order to build a possible diagnostic MPM tool using IMS. 
• Participants: 10 MPM patients, 10 healthy asbestos-exposed individuals (mean 
asbestos fiber year count 14,6 (5,5) fibre.years/cc) and 10 healthy non-exposed 
individuals were included after refraining from eating, drinking and smoking for 
at least 2 hours before sampling. 
 
• Breath sampling: Subjects breathed tidally with a nose clip for 3 minutes 
through a mouthpiece connected to a bacteria filter. Ten ml alveolar air was 
sampled via a CO2-controlled ultrasonic sensor and subsequently analyzed 
using the BioScout Multicapillary Column/Ion Mobility Spectrometer (MCC/IMS, 
B&S Analytik, Dortmund, Germany, Figure 1) [Westhoff M 2009], by using N2 as 
a carrier and drift gas. Per subject a background sample was taken to correct 
for contamination.  
 
• Breath analysis: Preprocessing of the data was done by base correction, 
normalization to the reactant ion peak (RIP), compensating RIP-tailing and 
smoothening techniques. Peaks of interest were visually selected in breath and 
background samples and their intensity (V) was analyzed and compared via on-
board VisualNow 3.2 software and SPSS v21 (IBM) using Mann-Whitney-U 
tests. Further selection of interesting peaks was done by looking at the alveolar 
gradient. MPM diagnostic accuracy was obtained by ROC-analysis. 
Peak 
MPM 
Intensity (V)* 
AEx 
Intensity (V)* 
Healthy 
Intensity (V)* 
p-value 
Between 
group 
significance
a 
AUCROC 
P6 0,001 [-0,008 – 0,006] 0,010 [-0,011 – 0,022] 0,082 [0,049 – 0,168] <0,01 †, # 0,300 
P9 0,087 [0,045 – 0,111] 0,102 [0,088 – 0,138] 0,011 [-0,018 – 0,025] <0,01 †, # 0,565 
P11 0,050 [0,025 – 0,058] 0,045 [0,032 – 0,054] 0,056 [0,045 – 0,071] 0,35 0,450 
P12 0,043 [0,024 – 0,077] 0,015 [0,011 – 0,022] 0,002 [-0,001 – 0,003] <0,01 ‡, † 0,865 
P16 -0,006 [-0,012 – -0,001] -0,003 [-0,006 – 0,003] 0,003 [-0,001 – 0,028] 0,03 † 0,235 
P19 0,021 [0,007 – 0,023] 0,034 [0,017 – 0,041] 0,031 [0,007 – 0,044] 0,63 0,350 
P20 0,023 [0,004 – 0,044] 0,047 [0,022 – 0,069] -0,002 [-0,009 – 0,005] 0,01 †, # 0,555 
P24 0,058 [0,031 – 0,089] 0,037 [0,013 – 0,067] -0,003 [-0,015 – 0,026] 0,01 †, # 0,770 
P26 0,000 [-0,002 – 0,007] 0,005 [-0,002 – 0,009] 0,008 [0,001 – 0,024] 0,33 0,355 
P27 0,002 [-0,002 – 0,010] 0,011 [-0,002 – 0,044] 0,009 [0,001 – 0,014] 0,47 0,360 
P28 0,002 [0,001 – 0,015] 0,001 [0,000 – 0,003] 0,000 [-0,001 – 0,002] 0,29 0,670 
P31 0,008 [0,000 – 0,022] 0,020 [-0,016 – 0,036] 0,007 [-0,016 – 0,013] 0,46 0,515 
P36 -0,001 [-0,010 – 0,001] 0,004 [-0,006 - 0,013] 0,018 [0,002 – 0,038] 0,05 † 0,265 
P37 0,005 [0,003 – 0,010]  0,002 [-0,014 – 0,004] 0,029 [0,007 – 0,039] <0,01 ‡, †, # 0,515 
*Median [IQR]. 1/K0: inversed reduced ion mobility. AEx: healthy asbestos exposed individual. AUCROC: Area under the 
receiver operator characteristic curve (accuracy in diagnosing MPM). MPM: Malignant Pleural Mesothelioma patient. RT: 
retention time. ap<0,05 for MPM vs. AEx (‡), MPM vs. Healthy (†) and  AEx vs. Healthy (#). 
MPM  
Patients 
AEx 
Individuals 
Healthy 
Individuals 
p-value 
N 10 10 10 
Gender (Male/Female) 8/2 9/1 8/2 1,00a 
Age (year)b 65,0 (59,0 – 67,0) 55,0 (54,0 – 56,0) 55,5 (49,0 – 61,0) <0,01 
Weight (kg)c 73,0 (11,8) 84,1 (12,7) 79,2 (9,8) 0,12 
Length (m)c 1,73 (0,06) 1,77 (0,06) 1,77 (0,08) 0,33 
BMI (kg/m²)c 24,3 (3,6) 26,9 (3,6) 25,1 (2,1) 0,20 
Smoking status (current/ex/non) 3/3/4 3/4/3 1/0/9 0,05a 
aFisher’s exact test, bMedian (IQR), cMean (SD). AEx: Asbestos-exposed. MPM: Malignant Pleural Mesothelioma. 
Table 1: Baseline characteristics. 
Table 2: VOC peak comparison. 
Figure 3: VOC peak visualization in the breath of an 
MPM patient (upper), an asbestos-exposed individual 
(middle) and a healthy non-exposed individual (lower). 
RT:  retention time. 1/K0: inverse reduced ion mobility. 
• Several VOCs of interest were derived from the breath according to the alveolar gradient. Four peaks (P12, P16, P24 and P36) had a significant effect in discriminating 
MPM patients from controls. However, only P12 and P24 have a relevant AUCROC to positively diagnose MPM. 
• The intensity of P12 was found to be significantly higher in MPM patients. Hence, this could be linked to MPM development and serve as an early diagnostic marker for 
MPM. P24 was significantly lower in non-exposed persons and could serve as a marker for asbestos-exposure. 
• GC-MS analysis and further large cohort studies including healthy unexposed individuals are ongoing in order to validate the accuracy of IMS as a diagnostic tool for 
MPM. Results need to be validated in an independent test set. 
Figure 4: ROC curves displaying the diagnostic 
accuracy of four selected peaks in discriminating 
MPM patients from asbestos-exposed and non-
exposed controls. 
Figure 2: Alveolar gradient  of selected peaks (peak intensity in 
breath – peak intensity in background samples; here shown as 
means). 
Figure 1: The MCC/IMS device 
(BioScout) with sampling unit 
(SpiroScout). 
